|
1
|
Khan SA, Emadossadaty S, Ladep NG, Thomas
HC, Elliott P, Taylor-Robinson SD and Toledano MB: Rising trends in
cholangiocarcinoma: Is the ICD classification system misleading us?
J Hepatol. 56:848–854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertuccio P, Bosetti C, Levi F, Decarli A,
Negri E and La Vecchia C: A comparison of trends in mortality from
primary liver cancer and intrahepatic cholangiocarcinoma in Europe.
Ann Oncol. 24:1667–1674. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghouri YA, Mian I and Blechacz B: Cancer
review: Cholangiocarcinoma. J Carcinog. 14:12015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sripa B and Pairojkul C:
Cholangiocarcinoma: Lessons from Thailand. Curr Opin Gastroenterol.
24:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sriamporn S, Pisani P, Pipitgool V,
Suwanrungruang K, Kamsa-ard S and Parkin DM: Prevalence of
Opisthorchis viverrini infection and incidence of
cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int
Health. 9:588–594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bundhamcharoen K, Odton P, Phulkerd S and
Tangcharoensathien V: Burden of disease in Thailand: Changes in
health gap between 1999 and 2004. BMC Public Health. 11:532011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle JW, Wasan H, Johnson P, Jones E,
Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, et al:
Gemcitabine alone or in combination with cisplatin in patients with
advanced or metastatic cholangiocarcinomas or other biliary tract
tumours: A multicentre randomised phase II study-The UK ABC-01
Study. Br J Cancer. 101:621–627. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Freeman AK and Morrison DK: 14-3-3
Proteins: Diverse functions in cell proliferation and cancer
progression. Semin Cell Dev Biol. 22:681–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neal CL, Yao J, Yang W, Zhou X, Nguyen NT,
Lu J, Danes CG, Guo H, Lan KH, Ensor J, et al: 14-3-3zeta
overexpression defines high risk for breast cancer recurrence and
promotes cancer cell survival. Cancer Res. 69:3425–3432. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matta A, Bahadur S, Duggal R, Gupta SD and
Ralhan R: Over-expression of 14-3-3zeta is an early event in oral
cancer. BMC Cancer. 7:1692007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishimura Y, Komatsu S, Ichikawa D, Nagata
H, Hirajima S, Takeshita H, Kawaguchi T, Arita T, Konishi H,
Kashimoto K, et al: Overexpression of YWHAZ relates to tumor cell
proliferation and malignant outcome of gastric carcinoma. Br J
Cancer. 108:1324–1331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bajpai U, Sharma R, Kausar T, Dattagupta
S, Chattopadhayay TK and Ralhan R: Clinical significance of 14-3-3
zeta in human esophageal cancer. Int J Biol Markers. 23:231–237.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Liu LX, Dong ZR, Shi GM, Cai JB,
Zhang PF, Ke AW, Yu JX, Zhou J and Fan J: Up-regulation of
14-3-3zeta expression in intrahepatic cholangiocarcinoma and its
clinical implications. Tumour Biol. 36:1781–1789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Frasor J, Chang EC, Komm B, Lin CY, Vega
VB, Liu ET, Miller LD, Smeds J, Bergh J and Katzenellenbogen BS:
Gene expression preferentially regulated by tamoxifen in breast
cancer cells and correlations with clinical outcome. Cancer Res.
66:7334–7340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang
H, Shen J, Zhao RY, Caraway NP, Katz RL, et al: Up-regulation of
14-3-3zeta in lung cancer and its implication as prognostic and
therapeutic target. Cancer Res. 67:7901–7906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neal CL, Xu J, Li P, Mori S, Yang J, Neal
NN, Zhou X, Wyszomierski SL and Yu D: Overexpression of 14-3-3zeta
in cancer cells activates PI3K via binding the p85 regulatory
subunit. Oncogene. 31:897–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yothaisong S, Dokduang H, Techasen A,
Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ and
Loilome W: Increased activation of PI3K/AKT signaling pathway is
associated with cholangiocarcinoma metastasis and PI3K/mTOR
inhibition presents a possible therapeutic strategy. Tumour Biol.
34:3637–3648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matta A, Siu KW and Ralhan R: 14-3-3zeta
as novel molecular target for cancer therapy. Expert Opin Ther
Targets. 16:515–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matta A, DeSouza LV, Shukla NK, Gupta SD,
Ralhan R and Siu KW: Prognostic significance of head-and-neck
cancer biomarkers previously discovered and identified using
iTRAQ-labeling and multidimensional liquid chromatography-tandem
mass spectrometry. J Proteome Res. 7:2078–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
